Brain Cancer Clinical Trials in Atlanta

Showing 41-60 of 176 trials

Active Not RecruitingEARLY Phase 1< 1 mile

Natural Progesterone for the Treatment of Recurrent Glioblastoma

NCT05091866

This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.

GliosarcomaRecurrent Glioblastoma

Emory University4 participantsStarted Apr 2022

Atlanta, Georgia, United States

Active Not RecruitingPhase 2< 1 mile

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

NCT04284774

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.

Malignant Solid NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Ectomesenchymoma+38 more

National Cancer Institute (NCI)5 participantsStarted Oct 2020

Birmingham, Alabama, United States • Anchorage, Alaska, United States • Mesa, Arizona, United States +169 more locations

Natural Progesterone for the Treatment of Recurrent Glioblastoma

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Brain Cancer Trials in Other Cities

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

9-ING-41 in Pediatric Patients With Refractory Malignancies.

A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Other Conditions in Atlanta